ResMed Reports Q3 Earnings with Revenue and Margin Growth, Announces CFO Transition and Acquisition
ResMed reported third-quarter revenue growth to $1.43 billion, a 290 basis point increase in gross margin to 62.8%, and a 21% rise in non-GAAP EPS. The company announced the retirement of its current CFO and named Aaron Bloomer as his successor. ResMed also revealed plans to acquire Noctrix for $340 million, expanding into the restless leg syndrome market.
Tickers: $RMD
Topics: acquisition_announcement cfo_transition gross_margin_expansion non_gaap_eps_increase revenue_growth